Blog

Jul 15, 2024, 13:21

Talha Badar: CRh as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia

Talha Badar shared on X:

“Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia

Pooled analysis of IDH1/2i and FLT3i in clinical trails, suggest CRh meaningful endpoint in improving outcome with non-myelosuppressive therapies.

Authors: Robert Q. Le, Donna Przepiorka, Haiyan Chen, Yuan Li Shen, E. Dianne Pulte, Kelly Norsworthy, Marc R. Theoret, R. Angelo De Claro.”

Talha Badar

Source: Talha Badar/X

Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.

Acute Myeloid Leukemia cancer Donna Przepiorka E. Dianne Pulte Haiyan Chen Kelly Norsworthy Marc R. Theoret OncoDaily Oncology R. Angelo De Claro Robert Q. Le Talha Badar Yuan Li Shen

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage